首页> 外文期刊>Journal of vascular surgery >Choice of a second vascular access in hemodialysis patients whose initial arteriovenous fistula failed to mature
【24h】

Choice of a second vascular access in hemodialysis patients whose initial arteriovenous fistula failed to mature

机译:在血液透析患者中选择第二血管接入,其初始动静脉瘘未能成熟

获取原文
获取原文并翻译 | 示例
       

摘要

ObjectiveWe have previously shown that arteriovenous fistulas (AVFs) are more expensive to create and to maintain than arteriovenous grafts (AVGs) in patients undergoing their first access. Because those for whom this first access fails may be a more disadvantaged group, we hypothesized that the cost of a second access may be different from that in the primary access group. With this in mind, we compared access costs in patients receiving a secondary AVF or AVG after their initial AVF failed to mature. MethodsThis was a retrospective cohort study of 92 patients who received a second vascular access (44 AVFs and 48 AVGs) after their first AVF failed to mature. We quantified the yearly frequency of percutaneous or surgical access interventions and catheter-related bacteremias (CRBs) using a computerized vascular access database. The costs associated with access procedures were quantified using the outpatient prospective payment schedule, and those related to hospitalization for CRB were determined from the diagnosis-related groups fee schedule. ResultsPatients receiving an AVF had fewer percutaneous procedures than those receiving an AVG (2.09 [95% confidence interval, 1.86-2.34] vs 2.61 [2.35-2.88];P?= .004), tended to undergo surgical interventions more frequently (1.21?[1.04-1.40] vs 1.00 [0.84-1.17];P?= .08), and experienced a similar yearly frequency of CRB hospitalizations (0.40 [0.31-0.52 vs 0.28 [0.20-0.38];P?= .07). Patients with a secondary AVF vs an AVG had a similar median yearly cost of percutaneous access interventions ($3567 [interquartile range, $1219-$4680] vs $4989 [$1570-$9752];P?= .14) and surgical access procedures ($6403 [$3494-$13,127] vs $4728 [$2563-$12,254];P?= .38) but a higher annual cost for CRBs ($3405 [$0-$12,825] vs $0 [$0-$5477];P?= .04). The total yearly access-related cost was similar in both groups ($19,477 [$9162-$36,916] vs $18,285 [$6850-$31,768];P?= .56). ConclusionsPatients undergoing a secondary AVF required more surgical procedures and sustained more bacteremia complications than patients undergoing a secondary AVG implantation. There was no significant difference in the total cost of access care for hemodialysis patients receiving a secondary AVF vs AVG.
机译:目标掌控前面表明,在进行首次接入的患者中,运动型瘘管(AVFS)更昂贵并维持在患者中的动静脉移植物(AVG)。因为该第一访问失败的人可能是一个更弱势的组,所以我们假设第二访问的成本可能与主访问组中的成本不同。考虑到这一点,我们在初始AVF未能成熟后获得接受次级AVF或AVG的患者的访问成本。方法是回顾性队列队列,对92名患者进行了92名患者,在他们的第一个AVF未能成熟后获得第二次血管访问(44 AVF和48个AVG)。我们使用计算机化血管访问数据库量化经皮或外科手术接入干预和导管相关菌血症(CRB)的年频率。使用门诊预期付款时间表量化与访问程序相关的成本,与CRB住院相关的费用取决于与诊断相关的团体费表确定。接受AVF的结果瓣膜的经皮手术较少(2.09 [95%[95%[95%置信区间] Vs 2.61 [2.35-2.88]; p?= .004),往往更频繁地进行外科干预(1.21? [1.04-1.40] vs 1.00 [0.84-1.7]; p?= .08),并且经历了类似的年度CRB住院频率(0.40 [0.31-0.52 Vs 0.28 [0.20-0.38]; p?= .07)。二级AVF与AVG的患者具有相似的中位数,经皮获取干预(3567美元[四分位数,1219-2680美元] VS $ 4989 [$ 1570- $ 9752]; P?= .14)和手术机访问程序($ 6403 [$ 3494 - $ 13,127] VS $ 4728 [$ 2563- $ 12,254]; p?= .38),但CRB的年度成本更高($ 3405 [$ 0- $ 12,825] VS $ 0 [$ 0- $ 5477]; p?= .04)。两组群体共年度访问相关成本相似($ 19,477 [9162- $ 36,916] VS $ 18,285 [$ 6850- $ 31,768]; p?= .56)。结论经历次级AVF的植物需要更多的外科手术和持续的细菌血症并发症,而不是经历过次级AVG植入的患者。血液透析患者接受次级AVF与AVG的血液透析患者的总成本没有显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号